Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Machine learning driven forward-reverse design of Ag-ZnO-PEEK nanocomposites for sustainable biomass and lipid enhancement in Chlorella vulgaris AK_123 with integrated anti-bacterial activity.

Scientific reports·2026
Same author

Covalent pan-TEAD inhibitors block YAP activity and demonstrate brain penetrance in a Hippo-dependent cancer model.

Nature communications·2026
Same author

Genomic landscape of drug binding and pharmacogenetic variation across diverse populations using SNPdrug3D.

Nature communications·2026
Same author

Deficiency in POLE Exonuclease Causes Synthetic Lethality in Highly Aneuploid Cancer Cells.

Cancer research·2026
Same author

TP53 mutation at codon 179 metabolically reprograms cancer cells to promote invasion.

Cancer gene therapy·2026
Same author

Hallmarks of Cancer: How did it inspire you?

Cell·2026
Same journal

Unveiling tumor heterogeneity by single cell RNA-sequencing: From basic considerations to clinical applications.

Seminars in cancer biology·2026
Same journal

Hidden architecture of resistance: The extracellular matrix in melanoma's immune landscape.

Seminars in cancer biology·2026
Same journal

Microfluidic technologies for extracellular vesicle isolation and analysis: Implications for translational applications in cancer therapy.

Seminars in cancer biology·2026
Same journal

Exploring glioblastoma microenvironment using organoids: opportunities, limitations, and emerging concepts.

Seminars in cancer biology·2026
Same journal

Special issue: Lipid metabolic alterations in cancer: Pathogenic mechanisms, therapies and common pathophysiology with cardiovascular disease.

Seminars in cancer biology·2026
Same journal

Systemic lipid metabolic alterations and the tumor microenvironment: A hidden driver of immune dysfunction.

Seminars in cancer biology·2026
See all related articles

Related Experiment Video

Updated: Jun 15, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

Modulating the p53 pathway.

Anwesha Dey1, David P Lane, Chandra S Verma

  • 1p53 Laboratory (A*STAR), 8A Biomedical Drive, Immunos, Singapore 138648, Singapore.

Seminars in Cancer Biology
|March 3, 2010
PubMed
Summary
This summary is machine-generated.

The p53 protein, a key cellular protector, can be therapeutically modulated to treat diseases. Recent strategies focus on targeting p53 regulators and function for enhanced drug efficacy.

More Related Videos

Purification of Ubiquitinated p53 Proteins from Mammalian Cells
10:55

Purification of Ubiquitinated p53 Proteins from Mammalian Cells

Published on: March 21, 2022

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence
04:56

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence

Published on: December 30, 2025

Related Experiment Videos

Last Updated: Jun 15, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

Purification of Ubiquitinated p53 Proteins from Mammalian Cells
10:55

Purification of Ubiquitinated p53 Proteins from Mammalian Cells

Published on: March 21, 2022

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence
04:56

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence

Published on: December 30, 2025

Area of Science:

  • Molecular Biology
  • Cellular Biology
  • Pharmacology

Background:

  • The p53 protein acts as a crucial transcription factor, safeguarding cells against various stressors.
  • p53 influences genes involved in cell cycle arrest, DNA repair, apoptosis, senescence, and metabolic alterations.
  • Modulating p53 activity presents a potential therapeutic avenue for diverse disease states.

Purpose of the Study:

  • To review recent advancements in modulating p53 function.
  • To outline current strategies for pharmacological intervention in the p53 pathway.
  • To highlight the development of novel animal models for studying p53 modulation.

Main Methods:

  • Strategies discussed include disrupting p53-negative regulator interactions.
  • Methods involve restabilizing mutant or misfolded p53 proteins.
  • Activation of p53-dependent transcription and systemic p53 modulation are also explored.

Main Results:

  • Pharmacological interventions targeting the p53 pathway are under investigation.
  • New approaches aim to enhance the therapeutic profiles of existing drugs by modulating p53.
  • Development of new mouse and zebrafish models facilitates in vivo research.

Conclusions:

  • Targeting the p53 pathway offers promising therapeutic strategies for various diseases.
  • Pharmacological modulation of p53 function is an active area of research.
  • Advanced animal models are crucial for validating these therapeutic developments.